Predict your next investment

HEALTHCARE | Pharmaceuticals / Drugs
integrativeenzymatics.com

See what CB Insights has to offer

Stage

Grant | Alive

Total Raised

$50K

Last Raised

$50K | 9 yrs ago

About Integrative Enzymatics

Established in 2011, Integrative Enzymatics (IE) is a biotechnology company dedicated to developing structure-based pharmaceutical products to treat chronic metabolic disorders. The company's primary offering is an intellectual property portfolio that consists of a pharmaceutical used for the treatment of Type I Diabetes Mellitus (T1DM) and Type II Diabetes Mellitus (T2DM).

Integrative Enzymatics Headquarter Location

3900 Paseo del Sol

Santa Fe, New Mexico, 87507,

United States

505-670-1334

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Integrative Enzymatics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Integrative Enzymatics is included in 1 Expert Collection, including Diabetes.

D

Diabetes

1,750 items

Integrative Enzymatics Patents

Integrative Enzymatics has filed 1 patent.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

4/12/2013

Clusters of differentiation, Cytokines, Immune system, Immunology, Nicotinic antagonists

Application

Application Date

4/12/2013

Grant Date

Title

Related Topics

Clusters of differentiation, Cytokines, Immune system, Immunology, Nicotinic antagonists

Status

Application

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.